1. **Title:** `G2019S raises the LRRK2 kinase floor more than the swelling gain`
**Mechanism:** G2019S may primarily increase constitutive catalytic output, producing higher baseline pRab10/pRab12 without materially changing the slope of the lysosomal volume-response curve. In this model, swelling still activates the same upstream lysosomal recruitment/activation circuit, but mutant cells start from a higher baseline rather than showing stronger fold-amplification.
**Target gene/protein/pathway:** `LRRK2` kinase domain, `RAB10`, `RAB12`, lysosomal stress signaling
**Supporting evidence:** G2019S often shows only modest endogenous pRab10 elevation compared with stronger ROC-COR mutants such as R1441G (PMID: `34125248`). G2019S carriers do show elevated phospho-Rab biomarkers in some contexts, including pRab12 in PBMCs (PMID: `39705401`). Membrane recruitment itself is sufficient to drive Rab phosphorylation, consistent with a recruitment-triggered pathway onto which G2019S could add a higher basal catalytic set-point (PMID: `35580815`).
**Falsifiable experiment:** Use isogenic WT and G2019S human iPSC-derived microglia and macrophages. Apply graded lysosomal swelling stimuli (`apilimod`, sucrose loading, low-dose chloroquine), then quantify baseline, EC50, maximal response, and fold-change for `pT73-RAB10`, `pS106-RAB12`, and `pS1292-LRRK2`. This hypothesis is supported if G2019S shifts baseline upward with little change in EC50 or maximal fold induction.
**Confidence:** `0.73`
2. **Title:** `The true mutant amplification may be in LYTL/JIP4 remodeling, not bulk pRab10 abundance`
**Mechanism:** G2019S may not dramatically amplify total Rab10 phosphorylation during swelling, but may disproportionately enhance downstream lysosomal tubulation/sorting (`LYTL`) through `JIP4`, `RAB10`, and `RAB35`. That would make the disease-relevant phenotype membrane remodeling and cargo export rather than simple phospho-signal height.
**Target gene/protein/pathway:** `JIP4`, `RAB10`, `RAB35`, `LRRK2`, LYTL pathway
**Supporting evidence:** LRRK2 drives lysosomal tubulation and vesicle sorting through JIP4 and Rab phosphorylation (PMID: `33177079`). Forced membrane localization of LRRK2 is sufficient to trigger `RAB10`, `RAB12`, and `JIP4` signaling, and pathogenic mutants show additive effects with membrane recruitment (PMID: `35580815`).
**Falsifiable experiment:** In WT versus G2019S knock-in microglia, induce lysosomal swelling and perform live-cell imaging of `LAMP1`, `JIP4`, `RAB10`, and tubule formation. Measure tubule number, duration, vesicle release, and dependence on `MLi-2` or `JIP4` knockdown. This hypothesis is supported if G2019S selectively increases LYTL kinetics/output more than it increases bulk pRab10.
**Confidence:** `0.69`
3. **Title:** `Phosphatase buffering makes G2019S look like a baseline defect in some cell types`
**Mechanism:** Whether G2019S appears as “higher baseline” versus “signal amplification” may depend on phospho-Rab turnover, especially via `PPM1H` and possibly `PPM1M`. Fast dephosphorylation of `pRab10` could compress dynamic range, masking true activation, while `pRab12` remains more sensitive in some compartments/cell types.
**Target gene/protein/pathway:** `PPM1H`, `PPM1M`, `RAB10`, `RAB12`, `LRRK2`
**Supporting evidence:** `PPM1H` is a key Rab phosphatase that reverses LRRK2-dependent Rab phosphorylation (PMID: `31663853`), and its localization strongly affects Rab10 dephosphorylation (PMID: `37889931`). Recent human PBMC data suggest `pRAB12` may outperform `pRAB10` as a G2019S biomarker (PMID: `39705401`).
**Falsifiable experiment:** In isogenic WT/G2019S microglia, perturb `PPM1H` or `PPM1M` by CRISPRi/overexpression, then run swelling-response curves for `pRab10` and `pRab12`. This hypothesis is supported if phosphatase suppression unmasks a stronger mutant-dependent dynamic response, especially for `Rab10`.
**Confidence:** `0.76`
4. **Title:** `G2019S preferentially amplifies volume-sensing in professional phagocytes and microglia`
**Mechanism:** The strongest mutant-dependent amplification may occur in cells with high endogenous `LRRK2` and constitutive endolysosomal load, especially macrophages and microglia, not neurons. In these cells, mutant LRRK2 could convert routine cargo-induced lysosomal swelling into exaggerated `Rab10`-dependent trafficking and inflammatory signaling.
**Target gene/protein/pathway:** `LRRK2`, `RAB10`, macropinocytosis/endolysosomal pathway, microglia/macrophages
**Supporting evidence:** LRRK2 and Rab10 are highly active in phagocytes and regulate macropinocytosis/signaling endosomes (PMID: `32853409`). Lysosomal stress and fibrillar α-synuclein drive LRRK2-Rab10 signaling and extracellular release in macrophage-lineage cells and microglia (PMID: `38313055`).
**Falsifiable experiment:** Compare WT and G2019S iPSC-derived microglia, peripheral monocyte-derived macrophages, and dopaminergic neurons under identical swelling/cargo-loading paradigms. Readouts: `pRab10`, `pRab12`, lysosome size, cytokines, and α-syn release. This hypothesis is supported if amplification is strong in microglia/macrophages but weak or absent in neurons.
**Confidence:** `0.81`
5. **Title:** `Pathogenic output is better captured by substrate switching toward Rab12 during chronic lysosomal stress`
**Mechanism:** G2019S may alter substrate preference under chronic lysosomal stress, with `RAB12` becoming a more informative readout than `RAB10`. If so, debate framing around Rab10 alone may miss genuine mutant amplification in lysosome-associated signaling.
**Target gene/protein/pathway:** `RAB12`, `RAB10`, `LRRK2`, granulovacuolar/lysosomal pathway
**Supporting evidence:** G2019S carrier PBMCs show elevated `pSer106-RAB12` (PMID: `39705401`). In human neurodegenerative brain tissue, both `pRAB12` and `pRAB10` accumulate in lysosome-like granulovacuolar structures, including in G2019S-linked disease (PMID: `41128923`).
**Falsifiable experiment:** Perform phosphoproteomic time-course profiling in WT and G2019S microglia after acute versus chronic lysosomal swelling. Quantify `pRab10`, `pRab12`, localization to `LAMP1`/GVB-like compartments, and phosphatase sensitivity. This hypothesis is supported if chronic stress selectively increases mutant `pRab12` or shifts the `pRab12:pRab10` ratio.
**Confidence:** `0.71`
6. **Title:** `Mutant LRRK2 turns lysosomal swelling into a feed-forward α-synuclein propagation loop`
**Mechanism:** Even if G2019S only modestly raises baseline kinase activity, that may be enough to amplify a thresholded loop in which swollen lysosomes recruit LRRK2, phosphorylate `RAB10`, promote vesicle sorting/exosome release, and increase extracellular pathogenic α-synuclein. Therapeutically, partial LRRK2 inhibition could break this loop without fully abolishing basal lysosomal surveillance.
**Target gene/protein/pathway:** `LRRK2-RAB10-JIP4`, lysosomal exocytosis/exosome pathway, α-synuclein handling
**Supporting evidence:** Lysosomal stress promotes α-synuclein release through the LRRK2-Rab10 pathway in macrophage-lineage cells and microglia (PMID: `38313055`). LRRK2-dependent lysosomal tubulation/sorting provides a plausible export mechanism downstream of Rab phosphorylation (PMID: `33177079`).
**Falsifiable experiment:** Load WT and G2019S microglia with α-syn PFFs, then induce controlled lysosomal swelling. Measure exosomal α-syn release, cathepsin release, neuron-to-microglia propagation, and rescue with partial versus full LRRK2 inhibition or `RAB10/JIP4` suppression. This hypothesis is supported if G2019S disproportionately increases cargo release/propagation relative to its effect on baseline pRab10.
**Confidence:** `0.84`
Most actionable discriminator: run **stimulus-response curves plus downstream trafficking phenotypes** in isogenic WT vs G2019S microglia/macrophages, measuring both **baseline and delta** for `pRab10`, `pRab12`, `JIP4/LYTL`, and **α-syn release**. That cleanly separates “higher floor” from “true amplification.”